Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

CMC and Bioprocess Blog

Execution-focused articles on CMC strategy, bioprocess scale-up, tech transfer, CDMO selection, and GMP readiness for process development scientists and manufacturing leaders scaling biologics into regulatory-ready therapies.

Innovation

What does it actually take to turn a cell therapy idea into a viable therapeutic—especially when the hurdles are higher than ever and every experiment carries real consequences for your runway?

Innovation

When it comes to neurodegenerative disease, few diagnoses evoke as much dread as Parkinson’s.

Innovation

How much of your research lives and dies on the bench—not because the idea isn’t sound, but because building reproducible, scalable biomaterials remains an unsolved puzzle?

Innovation

What if the real obstacle in 3D cell culture and tissue engineering isn’t the cells, but the very ground they grow on?

Innovation

The world of oncology constantly searches for breakthroughs, but few cancers present such stubborn challenges as glioblastoma (GBM).

Innovation

What if the answer to solid tumor therapy isn’t about making immune cells smarter—but about rethinking what a therapeutic cell can do?

Bioprocessing

Biologics development is full of hidden pitfalls, from selecting the right cell line to navigating analytical assessments that can make or break a therapy’s success.

Bioprocessing

How can small biotech companies navigate increasing molecular complexity, tight budgets, and the ever-present pressure to accelerate timelines while ensuring long-term process success?

Bioprocessing

Is your process model gathering dust while real-world decisions march on without it?

Bioprocessing

Bioprocess development lies at the heart of modern biotechnology, turning innovative molecules into life-changing therapies.

Bioprocessing

Bioreactor scale-up failures are still one of the top reasons promising cell therapies never reach the clinic. Traditional “power per volume” scale-up is often just a best guess—putting product quality and timelines at risk.

Bioprocessing

Can computational fluid dynamics (CFD) join the ranks of everyday tools in bioprocess engineering—right alongside spreadsheets and pH meters?

Data & Analytics

For years, protein engineering has struggled with a fundamental bottleneck: machine learning models, powerful as they are, have been starved of meaningful data.

Data & Analytics

Antibody therapeutics have transformed modern medicine, but for many scientists, developing new candidates still feels like searching for a needle in a haystack—a slow, expensive, and unpredictable process.

Data & Analytics

AI won’t replace your bioprocessing team—but it will make them more indispensable than ever.

Data & Analytics

What if the secret to reliable, real-time bioprocessing isn’t buried in another wet-lab experiment, but hiding inside your data—waiting for the right digital ally?

Data & Analytics

If you could run an experiment in your computer instead of the lab—and it actually gave you answers worth acting on—would you try it?

Data & Analytics

Imagine trimming years off biologics development—and catching problematic formulations long before the first pipette is even picked up.

Biotech Success

How do you know when your biotech startup is ready to sell—before the product is “perfect”?

Biotech Success

Most bioprocess innovation is dismissed as a “fool’s game”—until the skeptics are proven wrong.

Biotech Success

What happens when the solution to America’s insulin crisis isn’t a new molecule or fancy delivery device—but a new way of thinking about biotech itself?

Biotech Success

What if affordable insulin isn’t a scientific hurdle—but a financial and distribution puzzle no one’s been motivated to solve?

Biotech Success

Securing capital for biotech innovation has never been more challenging—or more crucial.

Biotech Success

Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Innovation

Cell and gene therapies rely on the fragile integrity of life itself—a single cell surviving through an unforgiving journey from lab to patient

Innovation

What if the breakthrough in AI-driven protein therapeutics hinges less on machine learning algorithms and more on a bold rethink of how companies share their most valuable resource—data?

Innovation

There’s a reason so many “picture-perfect” protein designs never make it past the computer screen: the leap from simulation to real-world function is wider than it looks.

Innovation

Is a future without heart attacks and strokes within reach—not just delayed, but truly reversed?

Innovation

What if the boldest therapeutic breakthroughs begin with questioning the very boxes we use to define drugs?

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.


No spam. Unsubscribe anytime.